MedTrace Logo

Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

NCT00790127 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2011-05-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of HQK-1001 administered daily for 8 weeks in subjects with beta thalassemia intermedia

Conditions

  • Beta Thalassemia

Interventions

DRUG

HQK-1001

HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days

DRUG

Placebo

Matching placebo capsules administered once a day, orally, for 56 days

Sponsors & Collaborators

  • HemaQuest Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Noppadol Siritanaratkul, MD · Siriraj Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Lebanon
  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790127 on ClinicalTrials.gov